Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease
- PMID: 22876027
- PMCID: PMC3413047
- DOI: 10.3748/wjg.v18.i29.3782
Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease
Abstract
Nonalcoholic fatty liver disease (NAFLD), defined by excessive liver fat deposition related to the metabolic syndrome, is a leading cause of progressive liver disease, for which accurate non-invasive staging systems and effective treatments are still lacking. Evidence has shown that increased ferritin levels are associated with the metabolic insulin resistance syndrome, and higher hepatic iron and fat content. Hyperferritinemia and iron stores have been associated with the severity of liver damage in NAFLD, and iron depletion reduced insulin resistance and liver enzymes. Recently, Kowdley et al demonstrated in a multicenter study in 628 adult patients with NAFLD from the NAFLD-clinical research network database with central re-evaluation of liver histology and iron staining that the increased serum ferritin level is an independent predictor of liver damage in patients with NAFLD, and is useful to identify NAFLD patients at risk of non-alcoholic steatohepatitis and advanced fibrosis. These data indicate that incorporation of serum ferritin level may improve the performance of noninvasive scoring of liver damage in patients with NAFLD, and that iron depletion still represents an attractive therapeutic target to prevent the progression of liver damage in these patients.
Keywords: Ferritin; Fibrosis; Iron overload; Nonalcoholic fatty liver disease; Steatohepatitis; Steatosis.
Figures

Similar articles
-
Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease.Liver Int. 2019 Jul;39(7):1325-1334. doi: 10.1111/liv.14096. Epub 2019 Mar 27. Liver Int. 2019. PMID: 30851216
-
Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study.Am J Gastroenterol. 2007 Jun;102(6):1251-8. doi: 10.1111/j.1572-0241.2007.01192.x. Epub 2007 Mar 27. Am J Gastroenterol. 2007. PMID: 17391316
-
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.Hepatology. 2012 Jan;55(1):77-85. doi: 10.1002/hep.24706. Epub 2011 Dec 6. Hepatology. 2012. PMID: 21953442 Free PMC article.
-
Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload.Diabetes Metab Res Rev. 2009 Jul;25(5):403-10. doi: 10.1002/dmrr.972. Diabetes Metab Res Rev. 2009. PMID: 19444865 Review.
-
Iron overload in nonalcoholic steatohepatitis.Adv Clin Chem. 2011;55:105-32. doi: 10.1016/b978-0-12-387042-1.00006-x. Adv Clin Chem. 2011. PMID: 22126026 Review.
Cited by
-
Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.Indian J Gastroenterol. 2015 May;34(3):200-8. doi: 10.1007/s12664-015-0572-5. Epub 2015 Jun 25. Indian J Gastroenterol. 2015. PMID: 26108652
-
Iron overload in alcoholic liver disease: underlying mechanisms, detrimental effects, and potential therapeutic targets.Cell Mol Life Sci. 2022 Mar 24;79(4):201. doi: 10.1007/s00018-022-04239-9. Cell Mol Life Sci. 2022. PMID: 35325321 Free PMC article. Review.
-
Efficacy of Hijamat (wet cupping therapy) in Iranian patients with nonalcoholic fatty liver disease: a controlled clinical trial.Turk J Med Sci. 2020 Apr 9;50(2):354-359. doi: 10.3906/sag-1907-82. Turk J Med Sci. 2020. PMID: 31999405 Free PMC article. Clinical Trial.
-
Pharmacological agents for nonalcoholic steatohepatitis.Hepatol Int. 2013 Dec;7 Suppl 2:833-41. doi: 10.1007/s12072-013-9482-8. Epub 2013 Nov 19. Hepatol Int. 2013. PMID: 26202298
-
Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease.World J Gastroenterol. 2014 Jun 28;20(24):7718-29. doi: 10.3748/wjg.v20.i24.7718. World J Gastroenterol. 2014. PMID: 24976709 Free PMC article. Review.
References
-
- Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–1850. - PubMed
-
- Day CP. From fat to inflammation. Gastroenterology. 2006;130:207–210. - PubMed
-
- Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–140. - PubMed
-
- Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617–649. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources